Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes.
Department of Ophthalmology and Visual Science, University of Texas Health Science Center-Houston, McGovern Medical School. Electronic address: helen.a.mintz-hittner@uth.tmc.edu.
Helen A
HA
Mintz-Hittner
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab